Navigation Links
Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
Date:5/21/2008

vels of Trp-p8 compared to the normal prostates. In comparing untreated BPH-induced prostates to those treated with D-3263, treatment with D-3263 resulted in a 39 percent reduction in prostate weight compared to control (p=0.004). In addition, treatment with D-3263 resulted in a 98 percent reduction (2221.2 pg/ml versus 43.1 pg/ml) in plasma dihydrotestosterone (DHT) levels (p=0.004) suggesting D-3263 is affecting androgen metabolism, which is a known stimulant for BPH and prostate cancer. These effects were seen in a dose-dependent manner, achieving efficacy comparable to finasteride. Histopathological examination post treatment with D-3263 indicated that reduction of prostate size and weight was due to a return to normalcy. Changes in Trp-p8 expression and plasma DHT levels correlated with both efficacy and dose.

About Trp-p8

Trp-p8 (also known as Trp-M8) was identified through Dendreon's in-house discovery efforts. It is an ion channel that is triggered by cold temperatures and small-molecule agonists. In normal human tissues Trp-p8 is expressed predominantly in the prostate where it is over-expressed in BPH and prostate cancer, as well as a range of other cancers including breast, lung and colon. Dendreon has synthesized bioavailable small molecule agonists that activate the Trp-p8 ion channel and induce cell death. The lead molecule, D-3263, is undergoing preclinical evaluation in anticipation of an investigational new drug application to be filed with the U.S. Food and Drug Administration for clinical evaluation in cancer patients.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response.
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
5. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
6. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
7. Napo Presents at ISPOR Meeting in Toronto
8. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
9. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014   Mast Therapeutics, Inc. (NYSE MKT: ... Edwin L. Parsley , D.O. has joined the Company ... Dr. Parsley has been actively engaged with ... February 2014.  He has served as Mast,s interim Chief ... Officer of Aires since April 2011.  Dr. Parsley previously ...
(Date:10/2/2014)... Oct. 1, 2014   Intarcia Therapeutics, Inc. ... four phase 3 clinical trials for ITCA 650 (exenatide, ... subcutaneous osmotic mini-pump). The first trial, FREEDOM-1, was a ... efficacy and safety of ITCA 650 in patients with ... 650 to be significantly superior to placebo for both ...
(Date:10/1/2014)... BOSTON , Oct. 1, 2014   ... market-leading provider of Anesthesia Information Management Systems (AIMS), ... Systems, LLC , a wholly owned subsidiary of ... healthcare information systems and connectivity solutions.  ... http://photos.prnewswire.com/prnh/20140930/149407 This partnership ...
Breaking Medicine Technology:Mast Therapeutics Announces Appointment Of Chief Medical Officer 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 3Mast Therapeutics Announces Appointment Of Chief Medical Officer 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3
(Date:10/2/2014)... October 02, 2014 BamboofloorChina.com is a ... products have won great appreciation from the global customers ... working hard to make more excellent items. All its ... to help all clients. , The company has ... to its website. Furthermore, the company’s marketing specialist ...
(Date:10/2/2014)... Oct. 1, 2014 (HealthDay News) -- Children with autism ... they,re fully capable of being more active, a small ... levels of 29 children, some with autism and some ... day of moderate physical activity and 70 more minutes ... 17 children with autism scored lower on strength, but ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. ... of Columbia now have a total of 500 confirmed cases ... infecting children since the summer, U.S. health officials reported ... in recent weeks, but it,s not clear what role -- ... said. Health officials are also trying to determine if ...
(Date:10/1/2014)... A new research study published today in the ... in patients older than 50 years with moderate or ... benefit. , Researchers from the University of Melbourne randomly ... knee pain to no acupuncture or sham or pretend ... weeks with participants and acupuncturists blinded to laser and ...
(Date:10/1/2014)... research suggests the adage that encourages people to keep ... when it comes to exercise. When walking, staying focused ... to it appear shorter and help people walk there ... this technique to walking while looking around the environment ... of exercise. , "People are less interested in exercise ...
Breaking Medicine News(10 mins):Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... and neck cancer that targets multiple peptides (parts of ... ,The researchers created the vaccine to ... mutated in most cancers and associated with poor clinical ... expresses unaltered, or "wild-type," p53 peptides in tumors. When ...
... critical genetic factor in the control of many aspects ... a genetic factor// , called a microRNA, in animal ... differentiation and development. ,MicroRNAS, or miRNAs, ... fine-tune levels of important proteins in cells. To learn ...
... was keenly interested in Buddhism and traveled to India in pursuit ... of 93. ,Born in 1913, Roaf spent his early ... the age of 13 and received a further scholarship in 1931 ... ,In 1934 Roaf's parents moved from London to Liverpool where he ...
... a universal problem. With a view to conserve water, ... the country.// ,In a press release the government ... India is about 1170 mm. However, there is very ... release further said that there had been considerable progress in ...
... Lebanon, a Mediterranean country, is considered notoriously image-conscious. It may ... militants// clashing fiercely all the time. ,But the ... ,Only that should explain why the Fist National Bank ... surgery. ,Its website dubs the 'plastic surgery loans' ...
... series of facts is one thing, understanding the big ... that// relational memory -- the ability to make logical ... is dependent on taking a break from studies and ... sleep. ,Led by researchers at Beth Israel ...
Cached Medicine News:Health News:Head and Neck Cancer Vaccine Targets Proteins to Create Immune Response 2Health News:Scientists Identify Critical Gene Factor in Heart Development 2Health News:Stress on Storage and Conservation of Rain Water by Govt of India 2Health News:Loans for Cosmetic Surgery in Lebanon 2Health News:To Understand the Big Picture, Give It Time -- and Sleep 2Health News:To Understand the Big Picture, Give It Time -- and Sleep 3
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Straight shafts. Overall length 3.9 inches....
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches....
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches....
Medicine Products: